

ASX ANNOUNCEMENT

R&D Tax Incentive Receipt

22nd December 2016: Analytica Ltd (ASX: ALT), is pleased to announce the receipt of \$1,157k from the Australian Taxation Office under the Research and Development incentive related to the financial year to 30th June 2016.

The Research and Development Tax Incentive is an initiative of the federal government to assist small companies to invest in essential research and development to be internationally competitive with new innovative products. This incentive is a welcome boost to our research funding and Analytica is grateful for the support.

The major focus of Analytica is to develop best in class, non-pharmaceutical, non-surgical treatment for pelvic floor muscle disorders, to dramatically improve women's quality of life. Over the last 12 months, case studies have been published in peer reviewed urological journals, app enhancements launched to track fluids and leakage, and our V2 clinical trial has reached a point where interim analysis is underway.

Analytica continues to invest in R&D to develop the version 3 product and the PeriCoach Data system.

The PeriCoach is more than the medical device. Powerful data analysis tools are also in development turning personal health data into global insights for areas of clinical procedure, product development opportunities, marketing tactics and product efficacy.

Analytica is a focused R&D company, but not all expenditure is eligible for the R&D incentive. The incentive's intent is to encourage Australian investment in fundamental research. Analytica's investment in global markets is centred upon growing the user database and paring with science to provide insights into women's pelvic health. Published clinical papers, case studies and presentations are demonstrating favourable results and are in front of the key specialists of the industry.

Analytica continues to build a compelling case for a multinational to invest.

Geoff Daly

CEO

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:





About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the USA.